Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2003 March;55(1) > Minerva Urologica e Nefrologica 2003 March;55(1):33-42

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA UROLOGICA E NEFROLOGICA

A Journal on Nephrology and Urology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,984


eTOC

 

REVIEWS  


Minerva Urologica e Nefrologica 2003 March;55(1):33-42

Copyright © 2003 EDIZIONI MINERVA MEDICA

language: English

Metabolic aspects of tacrolimus in renal trans-plantation. Consequences for the choice of an immunosuppressive regimen and for the management of post-transplant diabetes mellitus

Van Duijnhoven E. M., Boots J. M. M., Christiaans M. H. L., Van Hooff J. P.

Department of Internal Medicine, University Hospital Maastricht, Maastricht, The Netherlands


PDF  


The occur­rence of ­post-trans­plan­t dia­betes mel­lit­us (­PTDM) is an impor­tant com­pli­ca­tion ­after ­renal trans­plan­ta­tion asso­ciat­ed ­with an ­increased ­risk of chron­ic trans­plant dys­func­tion and of car­di­o­vas­cu­lar mor­bid­ity and mor­tal­ity. ­Both tacrol­i­mus and cyclo­spo­rine ­have ­been asso­ciat­ed ­with ­PTDM. In the ­initial stud­ies, ­PTDM ­seemed to ­occur ­more ­often in tacrol­i­mus treat­ed ­patients ­than in cyclo­spo­rine treat­ed ­patients. The mech­a­nism by ­which tacrol­i­mus ­could ­cause ­PTDM was ­unknown and the rel­a­tive ­roles of tacrol­i­mus and cor­ti­cos­ter­oids, ­which are ­often pre­scribed con­com­i­tant­ly ­with tacrol­i­mus, ­were ­unknown. In sev­er­al stud­ies we ­used fast­ing glu­cose and insu­lin lev­els to ­assess (periph­er­al) insu­lin resis­tance, and intra­ve­nous glu­cose tol­er­ance ­tests to ­assess insu­lin secre­tion by the pan­creat­ic β-­cells in ­response to a stim­u­lus (glu­cose ­load). ­Thus, we eval­u­at­ed the mech­a­nism by ­which tacrol­i­mus caus­es glu­cose meta­bol­ic dis­or­ders, ­risk fac­tors for glu­cose meta­bol­ic dis­or­ders dur­ing tacrol­i­mus treat­ment, the rel­a­tive ­roles of cor­ti­cos­ter­oids and tacrol­i­mus ­trough lev­els in glu­cose meta­bol­ic dis­or­ders, and ­also dif­fer­enc­es in glu­cose metab­olism ­between ­patients ­using tacrol­i­mus ver­sus ­patients ­using cyclo­spo­rine. ­Based on the ­results of ­these stud­ies and the avail­able lit­er­a­ture, the con­se­quenc­es for the ­choice of a pri­mary immu­no­sup­pres­sive ­agent and guide­lines for the treat­ment of ­PTDM dur­ing tacrol­i­mus-­based immu­no­sup­pres­sion are dis­cussed.

top of page

Publication History

Cite this article as

Corresponding author e-mail